QuidelOrtho Corporation (QDEL) Stock

Understand QuidelOrtho Corporation: how it makes money

QuidelOrtho builds diagnostic test instruments and the assays that run on them, selling to clinical labs, hospitals, and blood banks with revenue pulled in by long-term contracts and recurring consumable sales. Core lab chemistry and immunohematology account for roughly four-fifths of the mix, giving the business a sticky, contract-driven foundation.

The profit engine is the razor-and-blade model: instruments are placed in labs at thin margins, and multi-year contracts guarantee a recurring stream of assay and consumable sales that ultimately carry the profitability.

Business quality (Weak): Operating margin is negative (-4%), ROE is deeply negative, and the company is burning cash. The recurring-revenue model is sound in principle, but current execution and product mix have not yet supported a path to stable operating profit.

Bull case

• Core base is large and sticky: Management noted on the Q2 FY26 call that core labs and immunohematology represent about 75% of the company and grow at mid-single digits, underpinned by long-term contracts and installed instruments. That recurring bedrock limits downside even in soft quarterly readings.
• Nulexa opens a second growth curve: The Nulexa point-of-care molecular platform is described by management as scalable with menu-expansion potential. If adoption accelerates beyond the installed base, it gives QuidelOrtho a way to grow the smaller POC segment without relying on respiratory seasonality.

Bear case

• Cash burn is severe and worsening: Operating cash flow was negative $111 million and free cash flow was negative $136 million in the last reported quarter. Negative FCF of that magnitude on $600 million of revenue signals the cost structure has not yet been aligned with the current revenue base.
• Guidance cuts signal trajectory problem: Full-year revenue, EBITDA, and EPS guidance were all revised downward on the Q2 FY26 call, meaning management no longer believes the prior-year plan is achievable. A guide cut in the middle of the fiscal year typically resets peer expectations and compresses the multiple.
• China drag persists into 2026: Management flagged that China demand may remain pressured through the rest of 2026. For a global diagnostics company, a key manufacturing and distribution region sitting on the sidelines adds a lumpy, country-specific risk to the revenue trajectory.

QuidelOrtho Corporation earnings call transcripts

• QDEL Q2 FY26 earnings call transcript (reported 2026-08-06) · analysis
• QDEL Q4 FY25 earnings call transcript (reported 2026-02-11) · analysis

All QDEL earnings calls

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Neogen Corporation (NEOG)
• Myriad Genetics, Inc. (MYGN)
• Fortrea Holdings Inc. (FTRE)
• Medpace Holdings, Inc. (MEDP)
• Natera, Inc. (NTRA)
• RadNet, Inc. (RDNT)
• Charles River Laboratories International, Inc. (CRL)
• UL Solutions Inc. (ULS)